Advances and Perspectives in the Molecular Diagnosis of Head and Neck Cancer.
Advances and Perspectives in the Molecular Diagnosis of Head and Neck Cancer.
复制标题
DOI：
10.1517/17530050903338068
复制
发表时间：
2010-01-01
期刊：
影响因子：
--
通讯作者：
Califano JA
中科院分区：
文献类型：
--
作者：
Mydlarz WK;Hennessey PT;Califano JA
头颈鳞状细胞癌（HNSCC）是一种使人衰弱且致命的疾病。尽管放射治疗和手术治疗取得了重大进展，但头颈癌的 5 年生存率仍然只有 50%。早期检测已经取得了进展，但为了改善患者的治疗结果，需要更好的生物标志物和靶向治疗药物。新型生物标志物可以改善早期检测并提供数据来优化治疗策略和患者生存，并可能带来潜在有效的靶向治疗。报告 HNSCC 新型生物标志物的发现进展，并综述生物标志物在 HNSCC 分子诊断中的潜在用途。 1980 年至 2009 年英文文献 (PubMed) 综述。目前最广泛接受的 HNSCC 生物标志物是高危 HPV 状态。 EGFR 是另一种有前途的生物标志物，然而，需要进一步的研究来确定其预后益处。目前正在评估大量有前景的候选生物标志物，包括表观遗传、表达和基因组标志物。需要进行研究来验证来自足够动力的前瞻性队列的临床样本中这些生物标志物的敏感性和特异性，以便将这些发现成功转化为 HNSCC 的潜在分子诊断、预后和治疗生物标志物。
Head and neck squamous cell carcinoma (HNSCC) is a debilitating and lethal disease. Despite significant advances in radiotherapy and surgical management, the 5-year survival rate for head and neck cancer has remained a dismal 50%. Advances in early detection have been made, but to improve patient outcomes better biomarkers and targeted therapeutic agents are needed. Novel biomarkers can improve early detection and provide data to optimize therapeutic strategy and patient survival, and could lead to potentially effective targeted therapies. Report the advances in the discovery of novel biomarkers for HNSCC, and review the potential utility of biomarkers in the molecular diagnosis of HNSCC. A review of the English literature (PubMed) from 1980 to 2009. Currently the most widely accepted biomarker for HNSCC is high risk HPV status. EGFR is another promising biomarker, however, further research is necessary to determine its prognostic benefit. A large number of promising biomarker candidates are currently being evaluated including epigenetic, expression, and genomic based markers. Studies to validate the sensitivity and specificity of these biomarkers in clinical samples from adequately powered prospective cohorts are needed for successful translation of these findings into potential molecular diagnostic, prognostic, and therapeutic biomarkers for HNSCC.